medigraphic.com
ISSN 1405-8871 (Print)

2019, Number 3

<< Back Next >>

Aten Fam 2019; 26 (3)

Pheochromocytoma as a Secondary Cause of Hypertension

Castillo SM, de la Fuente PCH, Moranchel GL

Language: Spanish
References: 19
Page: 109-113
PDF size: 1358.70 Kb.


ABSTRACT

Pheochromocytoma is a rare tumor with an incidence in population of 1:100 000 patients per year, it occurs most often between the third and fourth decade of life, in both sexes, this tumor is characterized by secreting catecholamine (Noradrenaline, adrenaline and small amounts of dopamine). Its distribution and clinical presentation makes reference to the rule of ten, 10% are extra-adrenal; 10% are presented in children; 10% are multiple or bilateral; 10% are recurrent after surgery; 10% are malignant; 10% are family, 10% are discovered as adrenal incidentalomas and the remaining is distributed in different tissues, systems and other age groups. The clinical picture is mainly constituted by the headache classic triad, palpitations and diaphoresis. Because it is a major cause of correctable secondary arterial hypertension, its clinical suspicion and early treatment become relevant as a potentially curable pathology.


REFERENCES

  1. sirlin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji M. Pheochromocytoma: A review. Maturitas. 2014;77(3):229-38.

  2. Lam A. Update on paragangliomas and pheochromocytomas Turk Patoloji Derg. 2015;31(1):105-12.

  3. Farrugia F, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N et al. Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocrine regulations. 2017;51(3):168-81.

  4. Kiernan C, Solórzano C. Pheochromocytoma and paraganglioma. Surgical Oncology Clinics of North America. 2016;25(1):119-38.

  5. Hodin R, Lubitz C, Phitayakorn R, Stephen A. Diagnosis and management of pheochromocytoma. Current problems in surgery. 2014;51(4):151-87.

  6. Rimoldi S, Scherrer U, Messerli F. Secondary arterial hypertension: when, who, and how to screen? European Heart Journal. 2013;35(19):1245-54.

  7. Gunawardane P, Grossman A. Phaeochromocytoma and paraganglioma. In Hypertension: from basic research to clinical practice. 2016;956:239-59.

  8. Fishbein L. Pheochromocytoma and paraganglioma. Hematology/Oncology Clinics of North America. 2016;30(1):135-50.

  9. Pinto A, Barletta J. Adrenal tumors in adults. Surgical Pathology Clinics. 2015;8(4); 725-49.

  10. Pappachan J, Raskauskiene D, Sriraman R, Edavalath M, Hanna F. Diagnosis and Management of Pheochromocytoma: A Practical Guide to Clinicians. Current Hypertension Reports. 2014;16(7):442.

  11. Pappachan J, Tun N, Arunagirinathan G, Sodi R, Hanna F. Pheochromocytomas and Hypertension. Current hypertension reports. 2018;20(1):3.

  12. Zuber S, Wesley R, Prodanov T, Eisenhofer G, Pacak K, Kantorovich V. Clinical utility Feocromocitoma Aten Fam. 2019;26(3):109-113. http://dx.doi.org/10.22201/facmed.14058871p.2019.3.70038 of chromogranin A in SDH x-related paragangliomas. European journal of clinical investigation. 2014;44(4):365-71.

  13. Bílek R, Zelinka T, Vlček P, Dušková J, Michalský D, Novák K, et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiological research. 2017;66:S397-S408.

  14. Lenders J, Duh Q, Eisenhofer G, Gimenez- Roqueplo A, Grebe S, Murad M et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology. 2014;99(6):1915-42.

  15. Hamidi O, Young W, Iñiguez Ariza N, Kittah N, Gruber L, Bancos C et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. The Journal of Clinical Endocrinology & Metabolism. 2017;102(9):3296-3305.

  16. Crona J, Beuschlein F, Pacak K, Skogseid B. Advances in adrenal tumors 2018. Endocrine- Related Cancer. 2018;25(7):R405-R420.

  17. Iñiguez Ariza N, Kohlenberg J, Delivanis D, Hartman R, Dean D, Thomas M et al. Clinical, Biochemical, and Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large Adrenal Tumors. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2018;2(1):30- 9.

  18. Garcha A, Cohen D. Catecholamine excess: Pseudopheochromocytoma and beyond. Advances in chronic kidney disease. 2015;22(3):218-23.

  19. Plouin P, Amar L, Dekkers O. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. European Journal of Endocrinology. 2016;174(5):G1-G10.




2020     |     www.medigraphic.com